Literature DB >> 1350198

Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer.

D Shi1, G He, S Cao, W Pan, H Z Zhang, D Yu, M C Hung.   

Abstract

The c-erbB-2/neu gene encodes a transmembrane protein of 185 kDa (p185) with tyrosine kinase activity and extensive sequence homology to epidermal growth factor receptor. Amplification and overexpression of the c-erbB-2/neu gene has been shown in certain human tumors and is postulated to be important in human carcinogenesis. High levels of expression of the c-erbB-2/neu gene have been reported in non-small-cell lung cancer (NSCLC) cell lines and primary tumors from the United States. Since geographical and cultural factors may contribute to the development of certain types of cancer, we examined p185 examined p185 expression in 120 tumors from Chinese patients with lung cancers of different cell types and used immunohistochemical staining to determine the extent and general significance of p185 expression in human primary lung cancer. Our results demonstrate that 58.8% of the NSCLCs expressed p185 and that expression of p185 was observed only in NSCLC and not in small-cell lung cancers. Thirty-three of 41 adenocarcinomas and 24 of 55 squamous cell carcinomas among the NSCLCs examined were found to express p185 at levels different from those of normal lung. For the squamous cell carcinomas, p185 expression was correlated with lymph node metastasis (P less than 0.01), but for the adenocarcinomas, it was not (P greater than 0.05). In addition, expression of p185 in NSCLC was significantly more frequent in patients in advanced clinical stages. Our findings indicate that p185 expression is a frequent event and a general phenomenon in NSCLC and is correlated with poor clinical prognostic indicators, suggesting that expression of p185 may be of potential prognostic importance in NSCLC.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1350198     DOI: 10.1002/mc.2940050308

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  10 in total

1.  Antiproliferative and apoptotic activities of ketonucleosides and keto-C-glycosides against non-small-cell lung cancer cells with intrinsic drug resistance.

Authors:  J Paterson; C Uriel; M J Egron; J Herscovici; K Antonakis; M A Alaoui-Jamali
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

2.  Relationship of immunohistochemical biomarker expression and lymph node involvement in patients undergoing surgical treatment of NSCLC with long-term follow-up.

Authors:  Ana María Gómez; Jose Ramón Jarabo Sarceda; Jose Antonio L García-Asenjo; Cristina Fernandez; Susana Hernandez; Julian Sanz; Elena Fernandez; Joaquin Calatayud; Antonio Torres; Florentino Hernando
Journal:  Tumour Biol       Date:  2014-01-19

3.  The interrelationship between HER2 and CASP3/8 with apoptosis in different cancer cell lines.

Authors:  Kaifee Arman; Sercan Ergün; Ebru Temiz; Serdar Öztuzcu
Journal:  Mol Biol Rep       Date:  2014-09-05       Impact factor: 2.316

4.  Prediction of recurrence by quantification of p185neu protein in non-small-cell lung cancer tissue.

Authors:  M Diez; M Pollán; M Maestro; A Torres; D Ortega; A Gómez; A Sánchez; F Hernando; J L Balibrea
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.

Authors:  J A Kern; R J Slebos; B Top; S Rodenhuis; D Lager; R A Robinson; D Weiner; D A Schwartz
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

6.  Protein expression profile of primary human squamous cell lung carcinomas indicative of the incidence of metastases.

Authors:  Manfred Volm; Reet Koomägi; Jürgen Mattern; Thomas Efferth
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

7.  The role of transforming growth factor alpha production and ErbB-2 overexpression in induction of tumorigenicity of lung epithelial cells.

Authors:  A W Hamburger; A Fernandes; M Murakami; B I Gerwin
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

8.  Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections.

Authors:  P Pfeiffer; P P Clausen; K Andersen; C Rose
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

9.  Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.

Authors:  P M Schneider; H W Praeuer; O Stoeltzing; J Boehm; J Manning; R Metzger; U Fink; S Wegerer; A H Hoelscher; J A Roth
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

10.  Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma.

Authors:  Abby L Cosentino-Boehm; Jacqueline M Lafky; Tammy M Greenwood; Kimberly D Kimbler; Marites C Buenafe; Yuxia Wang; Adam J Branscum; Ping Yang; Nita J Maihle; Andre T Baron
Journal:  Diagnostics (Basel)       Date:  2013-01-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.